Report Shows Antibiotic Resistant Gonorrhea Increase

Report Shows Antibiotic Resistant Gonorrhea Increase

CDC - STD Surveillance, 2009 - Figure 32Gonorrhea is a sexually transmitted disease (STD) caused by the bacterium Neisseria Gonorrhoeae. Gonorrhea is a very common infectious disease among the sexually active young adults and teens. The Center for Disease Control and Prevention (CDC) estimates that more than 700,000 persons in the U.S. acquire the infection yearly. Unlike HIV, exchange of body fluids (e.g. ejaculation) does not necessarily have to occur for the bacterium to get transmitted. It can be spread through contact with the penis, vagina, mouth, or anus. Gonorrhea can also be spread from mother to child during delivery.

Six years ago, a serious case of antibiotic resistant gonorrhea surfaced. A group of antibiotics, fluoroquinolones, was crossed out of the list of recommended drugs for the treatment of uncomplicated gonorrhea in Oregon and California due to widespread resistance to it. In the last decade, there has been growing number of cases of antibiotic resistant gonorrhea, that are resistant to Cefixime CAS# 79350-37-1 which is taken orally, and the injectable form ceftriaxone. According to the CDC reports, the number of samples from patients showing greater than normal resistance to cefixime grew from 0.2% in 2000 to 1.4% in 2010, while ceftriaxone resistance grew from 0.1% to 0.3%.

Meanwhile, in the US, the CDC have recommended the additional use of Doxycycline CAS# 10592-13-9 and Azithromycin CAS# 83905-01-5 to the injectable ceftriaxone regimen in response to growing the antibiotic resistance.

The disease is serious, and the propensity of some of its strains to be antibiotic resistant dooms the patient to a lifetime of incurable infection that spreads to other organs. The pharmaceutical industry, especially LGM Pharma, is taking action along with the medical community’s fight against the superbug. Our third generation cephalosporin products, especially ceftriaxone are outsourced regularly to research institutions looking to understand the resistant strains and in the process, give the medical community a better picture and treatment option to combat it and its spread. The company is well aware of what’s happening in the world of medical research and development. These reports might seem inconsequential to some, but they actually weigh a lot if one took the time to examine it from a deeper perspective.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service